Company intelligence / Profile preview

Innovative Cellular Therapeutics

Rockville, Maryland, United Statesict-pulse.com ↗

Ownership: Private
Development stage: Other

Overview

GCC19CART has shown robust clinical activity for relapsed/refractory metastatic colorectal cancer. In a Chinese dose-escalation study at dose level 2 (2 x 10^6 CAR-T/kg), ORR was 50% with median overall survival exceeding 26 months. In the U.S. Phase I trial, at dose level 1 (1 x 10^6 CAR-T/kg), ORR was also 50% with mOS of 17 months; at dose level 2 (12 x 10^6 CAR-T/kg), ORR reached 80%, mOS not yet reached

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Partnerships

No major pharma partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Innovative Cellular Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovative Cellular Therapeutics.

Explore the full profile